| Literature DB >> 29402828 |
Kota Maekawa1, Masunari Shibata1, Hideki Nakajima2, Akane Mizutani3, Yotaro Kitano2, Masaru Seguchi1, Masayoshi Yamasaki3, Kazuto Kobayashi1, Takanori Sano2, Genshin Mori2, Tadashi Yabana4, Yutaka Naito3, Shigetoshi Shimizu2, Fumitaka Miya2.
Abstract
BACKGROUND: Only few studies have investigated the relationship between the histopathology of retrieved thrombi and clinical outcomes. This study aimed to evaluate thrombus composition and its association with clinical, laboratory, and neurointerventional findings in patients treated by mechanical thrombectomy due to acute large vessel occlusion.Entities:
Keywords: Acute ischemic stroke; Computed tomography; Endovascular revascularization; Pathology; Thrombus formation
Mesh:
Substances:
Year: 2018 PMID: 29402828 PMCID: PMC5836222 DOI: 10.1159/000486042
Source DB: PubMed Journal: Cerebrovasc Dis Extra ISSN: 1664-5456
Fig. 1.Histopathological analysis of a retrieved thrombus using the ImageJ software. a Pathology image of a thrombus stained with hematoxylin-eosin. b Leukocytes are depicted in red. Leukocytes represent 3% of the total composition in this image. c Erythrocytes are depicted in red. Erythrocytes represent 29% of the total composition in this image. d Fibrin is depicted in red. Fibrin represents 68% of the total composition in this image. These procedures were performed on all parts of the thrombus. This thrombus was finally categorized as fibrin rich.
Fig. 2.Histopathology of erythrocyte-rich and fibrin-rich thrombi. ×200. a Erythrocyte-rich thrombus displaying a predominance of erythrocyte infiltration and lower fibrin infiltration. b Fibrin-rich thrombus displaying a predominance of organized fibrin infiltration with few cellular elements.
Differences in preprocedural and procedural parameters between the two groups
| Erythrocyte rich ( | Fibrin rich ( | ||
|---|---|---|---|
| Age, years | 75.2±14 | 77.6±13.9 | 0.58 |
| Female, | 9 (50) | 13 (52) | 1 |
| Baseline NIHSS score | 20.3±9.2 | 20.2±6.3 | 0.97 |
| Diabetes mellitus, | 2 (11) | 2 (8) | 1 |
| Hypertension, | 6 (33) | 15 (60) | 0.16 |
| Anticoagulation agent, | 5 (28) | 6 (24) | 0.77 |
| Antiplatelet agent, | 4 (22) | 2 (8) | 0.18 |
| Stroke etiology according to TOAST criteria, | |||
| Large artery atherosclerosis (TOAST 1) | 3 (17) | 2 (8) | 0.63 |
| Cardioembolism (TOAST 2) | 9 (50) | 21 (84) | 0.01 |
| Other determined cause (TOAST 4) | 1 (6) | 0 (0) | 0.42 |
| Other undetermined cause (TOAST 5) | 5 (29) | 2 (7) | 0.07 |
| Occlusion site, | |||
| ICA | 8 (44) | 10 (40) | 1 |
| M1 proximal | 3 (17) | 5 (20) | 1 |
| M1 distal | 2 (11) | 5 (19) | 0.68 |
| M2 | 2 (11) | 4 (15) | 1 |
| Basilar artery | 3 (17) | 1 (4) | 0.29 |
| ASPECTS | 9.1±2.5 | 8.9±2.1 | 0.6 |
| Thrombus density, HU | 48.1 (24.7–55.1) | 32.1 (27–41.8) | 0.04 |
| Infusion of tissue plasminogen activator, | 10 (56) | 10 (40) | 0.49 |
| Symptom onset to puncture time interval, min | 225 (85–2,064) | 191 (60–1,324) | 0.65 |
| Mechanical thrombectomy device, | |||
| Stent retriever | 15 (83) | 23 (92) | 0.81 |
| Aspiration catheter | 13 (72) | 21 (84) | 0.77 |
| Procedure time, min | 24.5 (8–85) | 44 (13–129) | <0.01 |
| Arrival-to-recanalization time interval, min | 86.5 (32–146) | 110 (58–222) | 0.04 |
| Symptom onset-to-recanalization time interval, min | 256 (128–2,100) | 268 (100–1,367) | 0.4 |
| Number of recanalization maneuvers | 1.8±1.1 | 2.9±1.5 | 0.02 |
Values are presented as means ± SD or medians (range) unless specified otherwise. Procedure time is the time interval between catheterization of the balloon guiding catheter and recanalization. NIHSS, National Institutes of Health Stroke Scale; TOAST, Trial of Org 10172 in Acute Stroke Treatment; ICA, internal carotid artery; ASPECTS, Alberta Stroke Programme Early CT Score; HU, Hounsfield units.
Differences in final recanalization procedures between the study groups
| Erythrocyte rich ( | Fibrin rich ( | ||
|---|---|---|---|
| Stent retriever | 13 (72%) | 9 (36%) | 0.04 |
| Aspiration catheter | 4 (22%) | 14 (56%) | 0.06 |
| Adapt first | 1 (6%) | 2 (8%) | 1 |
| Stent first, adapt second | 1 (6%) | 8 (32%) | 0.08 |
| For distal migration | 2 (11%) | 4 (16%) | 1 |
| Intra-arterial injection of urokinase | 1 (6%) | 2 (8%) | 1 |
Fig. 3.Procedure time was correlated with erythrocyte infiltration (a), fibrin infiltration (b), and leukocyte infiltration (c).
Differences in outcome measures between the two groups
| Erythrocyte rich ( | Fibrin rich ( | ||
|---|---|---|---|
| TICI class 2b or 3 | 18 (100%) | 24 (96%) | 1 |
| mRS score 0–2 or no change at 90 days | 11 (71%) | 9 (36%) | 0.06 |
TICI, Thrombolysis in Cerebral Infarction; mRS, modified Rankin Scale.
n = 17.
Fig. 4.Differences in mean percentages of thrombus composition by Trial of Org 10172 in Acute Stroke Treatment (TOAST) class. Leukocyte (a), erythrocyte (b), and fibrin infiltration (c).